SREBP2 restricts osteoclast differentiation and activity by regulating IRF7 and limits inflammatory bone erosion

Area of Science:

• Cell Biology
• Bone Biology
• Molecular Biology

Background:

• Osteoclast formation is critical for bone remodeling but requires strict regulation to prevent excessive bone resorption.
• The precise mechanisms limiting osteoclastogenesis are not fully understood.
• Dysregulated osteoclast activity contributes to various bone diseases.

Purpose of the Study:

• To investigate the role of sterol regulatory element binding protein 2 (SREBP2) in regulating osteoclast differentiation and bone metabolism.
• To elucidate the molecular mechanisms underlying SREBP2's function in osteoclastogenesis.
• To explore SREBP2 as a potential therapeutic target for inflammatory bone loss.

Main Methods:

• Investigated SREBP2 expression during osteoclastogenesis.
• Utilized myeloid cell-specific SREBP2 knockout mouse models.
• Performed in vitro and in vivo studies of osteoclast formation and bone mass.
• Analyzed inflammatory bone loss in murine models of osteolysis and arthritis.
• Examined the role of interferon regulatory factor 7 (IRF7) as a downstream target.

Main Results:

• SREBP2 levels increased during the late phase of osteoclast differentiation.
• Ablation of SREBP2 in myeloid cells led to enhanced osteoclastogenesis and reduced bone mass.
• SREBP2 deficiency exacerbated bone destruction in inflammatory disease models.
• SREBP2's inhibitory effect on osteoclastogenesis is partly mediated by IRF7, independent of cholesterol biosynthesis.

Conclusions:

• SREBP2 acts as a crucial negative regulator of osteoclast formation and inflammatory bone loss.
• The SREBP2-IRF7 pathway represents a novel negative feedback mechanism controlling osteoclast differentiation.
• This study identifies a new therapeutic avenue for managing pathological bone destruction.